Congenital heart disease (CHD) is the most common organ malformation in humans, affecting approximately 1 of 125 newborns.
1 Critical CHD, defined as cases dependent on patency of the arterial duct for survival after birth, occurs in approximately 1 of 500 newborns and requires urgent medical attention to prevent circulatory collapse and early surgical management to stabilize the circulation.
2-4 Such critical cases, along with other severe types of CHD that require cardiac surgery during infancy to prevent heart failure and mortality, can be considered high-risk CHD. There is a global need to improve early diagnosis of such high-risk cases while overcoming inequalities in CHD care provision to achieve optimal outcomes.
4 Identifying such cases can be partially achieved by prenatal maternal ultrasound screening with detection in approximately half of cases, which in turn provides time for parental counselling, planning, and postnatal stabilization prior to surgery, even though these cases may often represent the most complex CHD forms.
5-7 The remainder of cases will rely on timely, postnatal diagnoses to minimize morbidity and mortality using clinical examinations or additional newborn pulse oximetry screening, although the latter continues to have modest sensitivity with diagnoses, such as aortic coarctation, that represent significant challenges.
8,9 We set out to develop quantitative DBS assays for the amino-terminal prohormone of brain natriuretic peptide (NT-proBNP) and interleukin 1 receptor-like 1 protein (IL-1 RL1; formerly known as soluble ST2) and evaluated these among a Swedish cohort of newborns. Biomarkers were selected based on published scientific data that have suggested a strong relationship between heart failure and elevated blood biomarker levels in various age groups and types of cardiac diseases, both in adults and children.
10-16 To address the need for timely and efficient detection of high-risk CHD in newborns, we hypothesized that the cardiovascular biomarkers NT-proBNP and IL-1 RL1 could aid this process if analyzed using minimal amounts of dried blood spot (DBS) samples, as commonly used in newborn screening programs.